Biocartis Group Gestion

Gestion contrôle des critères 2/4

We currently do not have sufficient information about the CEO.

Informations clés

Roger Moody

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	1.6yrs
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	3.1yrs
Durée moyenne du mandat des membres du conseil d'administration	6.8yrs

Mises à jour récentes de la gestion

Recent updates

Investors Give Biocartis Group NV (EBR:BCART) Shares A 31% Hiding

Jun 17

Analysts Have Been Trimming Their Biocartis Group NV (EBR:BCART) Price Target After Its Latest Report

Feb 27

What Type Of Returns Would Biocartis Group's(EBR:BCART) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jul 28

PDG

Roger Moody

1.6yrs

Titularisation

Mr. Roger Moody is Chief Executive Officer of Biocartis Group NV from April 24, 2023. Mr. Moody has experience in the technology and healthcare industry and brings a unique combination of deep knowledge of...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Piet Houwen	Chief Operating Officer	5.6yrs	pas de données	pas de données
Roger Moody	Chief Executive Officer	1.6yrs	pas de données	pas de données
George Cardoza	CFO & Head of Service Delivery	1.3yrs	pas de données	pas de données
Benoit Devogelaere	Chief Technology Officer	6.9yrs	pas de données	pas de données
W. Korn	Chief Medical & Scientific Officer	less than a year	pas de données	pas de données
Renate Degrave	Head of IR & Corporate Communications	no data	pas de données	pas de données
Erik Vossenaar	Senior Vice-President of Corporate Development & Strategy	less than a year	pas de données	pas de données
Susy Spruyt	Head of People & Organization	9.8yrs	pas de données	pas de données
Erwin Sablon	Head of R&D and Alliance Management	12.3yrs	pas de données	pas de données
Reginald Van Genechten	Head of Manufacturing & Supply Chain	8.7yrs	pas de données	pas de données
Sarah Baudenelle	Head of Operations & On-Market Product Support	1.2yrs	pas de données	pas de données
Karlien Hermans	Head of Quality & Regulatory	3.1yrs	pas de données	pas de données

3.1yrs

Durée moyenne de l'emploi

56yo

Âge moyen

Gestion expérimentée: BCART's management team is considered experienced (3.1 years average tenure).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Christian Reinaudo	Independent Director	6.5yrs	€84.00k	pas de données
Herman Verrelst	Independent Chairman of the Board	7.2yrs	€436.78k	pas de données
Jean-Louis Vincent	Member of Scientific Advisory Board	no data	pas de données	pas de données
Ann-Christine Sundell	Non Executive Independent Director	6.8yrs	€47.50k	pas de données
Pasi Antero Janne	Member of Scientific Advisory Board	no data	pas de données	pas de données
Geert Maertens	Chairman of Scientific Advisory Board	no data	pas de données	pas de données
Alberto Bardelli	Member of Scientific Advisory Board	no data	pas de données	pas de données
Eric Cutsem	Member of Scientific Advisory Board	no data	pas de données	pas de données
Josep Tabernero Caturla	Member of Scientific Advisory Board	no data	pas de données	pas de données
Bert Niesters	Member of Scientific Advisory Board	no data	pas de données	pas de données
Luc Gijsens	Non-Executive Independent Director	6.8yrs	€49.50k	pas de données
Michael Press	Member of Scientific Advisory Board	no data	pas de données	pas de données

6.8yrs

Durée moyenne de l'emploi

66yo

Âge moyen

Conseil d'administration expérimenté: BCART's board of directors are considered experienced (6.8 years average tenure).

Biocartis Group Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Biocartis Group Ordinary Shares to be Deleted from OTC Equity

New major risk - Financial data availability

New minor risk - Financial data availability

Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress

First half 2023 earnings released

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV to Report First Half, 2023 Results on Sep 26, 2023

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

Investors Give Biocartis Group NV (EBR:BCART) Shares A 31% Hiding

New major risk - Share price stability

Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Biocartis Group NV Announces the Launch of the First Assay Developed With the New Idylla™ Flex Technology

Biocartis Group NV has completed a Follow-on Equity Offering in the amount of €25.107699 million.

Price target decreased to €4.75

Insufficient new directors

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV to Report Q1, 2023 Results on Apr 20, 2023

First half 2022 earnings released: EPS: €0 (vs €0.65 loss in 1H 2021)

Biocartis Group NV Provides Earnings Guidance for 2022

Biocartis Group NV Obtains ISO 27001 Certification for Information Security Management

Biocartis Group NV Announces Launch of its Rapid CE-marked IVD Idylla GeneFusion Panel for Fast Treatment Decisions in Lung Cancer

Biocartis Group NV announces New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ Genefusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods

Price target decreased to €4.75

Insufficient new directors

Biocartis Group NV Reconfirms Earnings Guidance of 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Analysts Have Been Trimming Their Biocartis Group NV (EBR:BCART) Price Target After Its Latest Report

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Biocartis Group NV Provides Earnings Guidance for the Year 2022

Biocartis Group NV Announces Publication of Large New Study Comparing the Difference in Turnaround Time Between In-House Automated Rapid Pcr3-Based EGFR Analysis and Next-Generation Sequencing

Price target decreased to €6.50

Insufficient new directors

Biocartis’ Idylla™ SARS-CoV-2 Testing Successfully Detects Omicron Variant

Biocartis Group NV Announces Restart of Its High-Throughput Cartridge Manufacturing Line

Biocartis Group NV Receives EUR 1.4 Million Grant to Support Development of New Idylla™ Technology

Biocartis Group NV Reconfirms Production Guidance of 2021

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

We Think Biocartis Group (EBR:BCART) Has A Fair Chunk Of Debt

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

New 90-day low: €4.41

Revenue and earnings beat expectations

What Kind Of Shareholders Own Biocartis Group NV (EBR:BCART)?

What We Learned About Biocartis Group's (EBR:BCART) CEO Compensation

Biocartis Group NV Announces Ten Idylla™ Studies to be Published at Virtual AMP (US) Annual Meeting

Biocartis Group NV Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay

Biocartis Group NV to Report Q3, 2021 Results on Nov 10, 2021

Biocartis and Geneprodx to Collaborate on Fully Automated Thyroidprint Test on Idylla

Biocartis Group NV Announces Partnership with Endpoint Health to Develop Novel Companion Diagnostic in Critical Illness

Price target lowered to €7.75

New 90-day low: €4.16

Biocartis Group Nv Announces Market Release of Septicyte® Rapid Test on Idylla™

First half earnings released

Biocartis Group NV to Report Fiscal Year 2020 Final Results on Apr 01, 2021

New 90-day high - €5.02

What Can We Learn About Biocartis Group's (EBR:BCART) CEO Compensation?

New 90-day high - €5.01

What Type Of Returns Would Biocartis Group's(EBR:BCART) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

PDG

Titularisation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen